Annexin A5
Recombinant proteinexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 21, 2020 (NCT04850339)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095265 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07259928 | Phase 2 | Nov 7, 2025 | Annexin Pharmaceuticals AB |
| NCT05532735 | Phase 2 | Aug 24, 2022 | Annexin Pharmaceuticals AB, InFocus Clinical Research |
| NCT05133791 | Phase 1 | Sep 23, 2021 | University of Groningen |
| NCT04748757 | Phase 2 | Apr 20, 2021 | Government of Ontario, London Health Sciences Foundation, University of Western Ontario |
| NCT04850339 | Phase 1 | Dec 21, 2020 | Annexin Pharmaceuticals AB |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Annexin Pharmaceuticals AB | For profit | 3 | 3 | 2 | 2020 |
| Government of Ontario | Government | 1 | 0 | 1 | 2021 |
| InFocus Clinical Research | For profit | 1 | 0 | 1 | 2022 |
| London Health Sciences Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Western Ontario | Academic/Hospital | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1